ABL Bio Inc.
A global leader in bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases.
64 employees · est. 2016 · Korea South
Oxford BioTherapeutics
Redefining the cancer-immune synapse for novel immune checkpoint mechanisms
66 employees · est. 2004 · Oxford, United Kingdom
Oxford BioTherapeutics is the older company (2016 vs 2004).
Side-by-Side Comparison
| Metric | ABL Bio Inc. | Oxford BioTherapeutics |
|---|---|---|
| Founded | ||
| Founded | 2016 | 2004 older |
| Headquarters | ||
| Headquarters | Korea South | Oxford, United Kingdom |
| Employees | ||
| Employees | 64 | 66 |
| Industry | ||
| Industry | Biotechnology, Health Care | Biotechnology, Health Care, Health and Wellness |
| Funding Stage | ||
| Funding Stage | IPO | Unknown |
| Total Funding | ||
| Total Funding | $49.12B | $28.09M |
| Funding Rounds | ||
| Funding Rounds | 6 | 11 |
| Services | ||
| Services | Development of innovative therapeutic drugs, Research and development of cancer and neurodegenerative disease treatments, Creating and managing biopharmaceutical platforms, Clinical trials and regulatory approval processes | Development of targeted cancer therapies, Integration of OGAP-Verify proteomic platform, Clinical-stage asset management, Therapeutic antibody generation |
| Target Customers | ||
| Target Customers | Healthcare providers, Patients with cancer and neurodegenerative diseases, Pharmaceutical companies, Medical researchers | Oncology patients, Pharmaceutical partners, Biotechnology collaborators |
| Taxonomy | ||
| Taxonomy | Bispecific Antibody Therapeutics, Immuno-Oncology, Neurodegenerative Diseases, Grabody-T, Grabody-I, Grabody-B, 4-1BB Engagement, Blood-Brain Barrier Penetration, Clinical Stage Drug Candidates, Pre-Clinical Stage Drug Candidates, Antibody Drug Conjugate, CNS Targets, Strategic Partnerships, Next-Generation Antibody | Clinical Stage Oncology, Immuno-Oncology, Antibody-Drug Conjugates, Cancer Therapeutics, Immune Checkpoint Mechanisms, Targeted Medicines, OGAP Platform, Cancer Membrane Proteomics, Human Protein Databases, Companion Diagnostics, Discovery Partnerships, Novel Antibody Therapeutics, Pipeline Development, Disease Management, Antibody Development Partnerships |
| Website | ||
| Website | ablbio.com | oxfordbiotherapeutics.com |
About ABL Bio Inc.
ABL Bio Inc., founded in 2016 and headquartered in Korea South, stands as a prominent figure in the biotechnology space. Known for being a global leader in bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases, the company has carved out a niche in delivering innovative...
About Oxford BioTherapeutics
Oxford BioTherapeutics (OBT), founded in 2004 and headquartered in the United Kingdom, is at the forefront of cancer therapeutics innovation. The company is uniquely positioned with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies aimed at addressing sign...
We will tell you when either one moves
BounceWatch watches ABL Bio Inc. and Oxford BioTherapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at ABL Bio Inc. and Oxford BioTherapeutics — by email.
Frequently Asked Questions
Compare ABL Bio Inc. with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at ABL Bio Inc. on 15 Jun 2026, and Oxford BioTherapeutics on 22 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
